Should You Stay or Go? When to Change Treatments
Advice from rheumatologists for changing psoriatic arthritis medications, including side effects, symptoms, and insurance coverage. (Source: WebMD Health)
Source: WebMD Health - October 14, 2022 Category: Consumer Health News Source Type: news
PsA Guidelines Need Improvement on Conflicts of Interest PsA Guidelines Need Improvement on Conflicts of Interest
Many authors of psoriatic arthritis guidelines from the American College of Rheumatology and the Japanese Dermatological Society have undisclosed financial conflicts of interest.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 10, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news
Why Some Psoriatic Disease Symptoms Are Unreported
Why do symptoms of psoriasis, psoriatic arthritis, and psoriatic disease get missed? Find out from a psoriatic disease advocate. (Source: WebMD Health)
Source: WebMD Health - October 10, 2022 Category: Consumer Health News Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Inflammatory Bowel Disease, Psoriasis May Be Causally Related
THURSDAY, Sept. 22, 2022 -- Inflammatory bowel disease (IBD) appears to have a causal impact on psoriasis, especially psoriatic arthritis (PsA), and total psoriasis and PsA are associated with Crohn disease (CD), according to a study recently... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 22, 2022 Category: Pharmaceuticals Source Type: news
Psoriasis Patients Find Psoriatic Arthritis Screening Worthwhile
TUESDAY, Sept. 20, 2022 -- Psoriatic arthritis (PsA) screening is acceptable to patients with psoriasis whether they are diagnosed with PsA or not, according to a research letter published online Aug. 17 in the British Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2022 Category: Pharmaceuticals Source Type: news
S2 Episode 4: Cardiovascular Risk in Patients With Psoriatic Arthritis S2 Episode 4: Cardiovascular Risk in Patients With Psoriatic Arthritis
Drs Stanley Cohen and Atul Deodhar discuss cardiovascular risk in patients with psoriatic arthritis and the impact of effective treatment.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 20, 2022 Category: Consumer Health News Tags: Rheumatology InDiscussion Source Type: news
Causal Effect ID'd for IBD With Psoriasis, Psoriatic Arthritis
WEDNESDAY, Sept. 14, 2022 -- There seems to be a causal effect between inflammatory bowel disease and psoriasis and psoriatic arthritis, according to a study published online Sept. 14 in JAMA Dermatology.
Dennis Freuer, Ph.D., from the University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 14, 2022 Category: Pharmaceuticals Source Type: news
Differentiating Axial Disease in PsA Versus AS With Psoriasis Differentiating Axial Disease in PsA Versus AS With Psoriasis
Some identifiers of patients with isolated axial psoriatic arthritis were older age at diagnosis, psoriatic nail lesions, and absence of inflammatory back pain.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 9, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news
TREMFYA ®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study
Beerse, Belgium, 8 September 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for TREMFYA®▼(guselkumab) from the ongoing Phase 3b GUIDE study, which is designed to understand the impact of early intervention and potential dosing interval flexibility on the long-term disease course in adult patients with moderate to severe plaque psoriasis (Pso). These new data demonstrated that “super responders”a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score <3) at a rate that was non-inferior to ...
Source: Johnson and Johnson - September 8, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Outcomes of Drug Therapy in Patients With Psoriatic Arthritis Axial Disease
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 24, 2022 Category: Orthopaedics Tags: CME Article Source Type: news
S2 Episode 3: Treating Psoriatic Arthritis With Methotrexate and csDMARDs S2 Episode 3: Treating Psoriatic Arthritis With Methotrexate and csDMARDs
Drs Stanley Cohen and Caylib Durand discuss the treatment paradigm for psoriatic arthritis and the role of methotrexate and other conventional synthetic disease-modifying antirheumatic drugs.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2022 Category: Consumer Health News Tags: Rheumatology InDiscussion Source Type: news
Ustekinumab Becomes Second Biologic Approved for PsA in Kids Ustekinumab Becomes Second Biologic Approved for PsA in Kids
The approval is based on an extrapolation of data from adult trials in active psoriatic arthritis and adult and pediatric studies in moderate to severe plaque psoriasis.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 2, 2022 Category: Dermatology Tags: Rheumatology News Alert Source Type: news
STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
